Rubraca
Rubraca ingredients
| Active ingredient | Strength |
|---|---|
| Rucaparib Camsylate | 250 mg/1, 200 mg/1, 300 mg/1 |
What Rubraca is used for
The FDA lists the approved uses on the official label (below). In the EU, rucaparib is approved as Rubraca for:
Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Rubraca
- Generic name
- Rucaparib
- Made by
- pharmaand GmbH
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Poly(ADP-Ribose) Polymerase Inhibitor
- FDA approval
- New drug application (NDA) NDA209115
- On the US market since
- 2016
Official information
- MedlinePlus drug information (search for Rucaparib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rubraca?
Rubraca (Rucaparib) is a cancer medicine made by pharmaand GmbH, approved by the US FDA.
What are the ingredients of Rubraca?
Rubraca contains Rucaparib Camsylate (250 mg/1, 200 mg/1, 300 mg/1).
Is Rubraca approved in Europe?
The same active substance is approved in the EU as Rubraca.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA